These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 8814995

  • 21. A possible role for cysteine proteinase and its inhibitors in motility of malignant melanoma and other tumour cells.
    Boike G, Lah T, Sloane BF, Rozhin J, Honn K, Guirguis R, Stracke ML, Liotta LA, Schiffmann E.
    Melanoma Res; 1992; 1(5-6):333-40. PubMed ID: 1422189
    [Abstract] [Full Text] [Related]

  • 22. Inhibition of proteolytic enzymes in the in vitro amnion model for basement membrane invasion.
    Persky B, Ostrowski LE, Pagast P, Ahsan A, Schultz RM.
    Cancer Res; 1986 Aug; 46(8):4129-34. PubMed ID: 3524801
    [Abstract] [Full Text] [Related]

  • 23. Retinoic acid-enhanced invasion through reconstituted basement membrane by human SK-N-SH neuroblastoma cells involves membrane-associated tissue-type plasminogen activator.
    Tiberio A, Farina AR, Tacconelli A, Cappabianca L, Gulino A, Mackay AR.
    Int J Cancer; 1997 Nov 27; 73(5):740-8. PubMed ID: 9398056
    [Abstract] [Full Text] [Related]

  • 24. [Role of matrix-degrading enzymes in melanoma progression].
    Hofmann UB, Becker JC, Bröcker EB.
    Hautarzt; 2002 Sep 27; 53(9):587-95. PubMed ID: 12207262
    [Abstract] [Full Text] [Related]

  • 25. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
    Masson V.
    Bull Mem Acad R Med Belg; 2006 Sep 27; 161(5):320-6. PubMed ID: 17283905
    [Abstract] [Full Text] [Related]

  • 26. Plasminogen activators and matrix metalloproteinases in angiogenesis.
    Mignatti P, Rifkin DB.
    Enzyme Protein; 1996 Sep 27; 49(1-3):117-37. PubMed ID: 8797002
    [Abstract] [Full Text] [Related]

  • 27. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H.
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug 27; 48(8):623-32. PubMed ID: 8808830
    [Abstract] [Full Text] [Related]

  • 28. Neutral proteinases and their inhibitors in the loosening of total hip prostheses.
    Takagi M.
    Acta Orthop Scand Suppl; 1996 Oct 27; 271():3-29. PubMed ID: 8975533
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Plasminogen activators play an essential role in extracellular-matrix invasion by lymphoblastic T cells.
    Reiter LS, Spertini O, Kruithof EK.
    Int J Cancer; 1997 Feb 07; 70(4):461-6. PubMed ID: 9033655
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Effects of polysulfated glycosaminoglycan and triamcinolone acetonid on the production of proteinases and their inhibitors by IL-1alpha treated articular chondrocytes.
    Sadowski T, Steinmeyer J.
    Biochem Pharmacol; 2002 Jul 15; 64(2):217-27. PubMed ID: 12123742
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Plasminogen activators in abdominal aortic aneurysmal disease.
    Reilly JM.
    Ann N Y Acad Sci; 1996 Nov 18; 800():151-6. PubMed ID: 8958990
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.